

Certificate of Analysis

RIPK1, active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 16-022, 16-022-K, 16-022M

Parent Lot # D16KP002N

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: C-terminal 6His-tagged, recombinant, human RIPK1 amino acids 8-322 co-expressed with untagged human CDC37, full length by baculovirus in Sf21 insect cells. Purified using immobilized metal affinity chromatography. Purity 77% by SDS-PAGE and Coomassie blue staining. MW = 37kDa.

Specific Activity (Parent lot# D16KP002N): 7U/mg, where one unit of RIPK1 activity is defined as 1nmol phosphate incorporated into 0.33mg/ml myelin basic protein per minute at 30°C with a final ATP concentration of 100µM.

Formulation: 2.99mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 23–498ng of this lot of enzyme phosphorylated 0.33mg/ml myelin basic protein in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as RIPK1 with the translated sequence listed on page three.



SDS-PAGE and Coomassie Stain: Purity was assessed by SDS-PAGE and Coomassie blue staining using 3µg of RIPK1, active.

Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

1. **5 x Reaction Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA.
2. **Myelin basic protein:** Use at a final assay concentration of 0.33mg/ml. Prepare a 3.33mg/ml stock and add 2.5µl of stock per assay point.
3. **Manganese chloride:** Use at a final assay concentration of 10mM. Prepare a 100mM stock and use 2.5µl per assay point.
4. **RIPK1, active:** Dilute with 20mM MOPS/NaOH pH7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 23–498ng per assay point.
5. **[γ -³³P]ATP:** 2.5 x MgAc/[γ -³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ -³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required).

Assay Procedure (96 well plate format):

1. Add 5µl of 5 x reaction buffer per assay to wells.
2. Add 2.5µl of myelin basic protein.
3. Add **2.5µl (23–498ng) RIPK1, active.**
4. Add 2.5µl of 100mM manganese chloride
5. Add 2.5µl of dH₂O.
6. Add 10µl of diluted [γ -³³P]ATP mixture.
7. Incubate for 30 minutes at 30°C.
8. Stop the reaction by adding 5µl of 3% phosphoric acid.
9. Transfer a 10µl aliquot onto the appropriate area of a **P30 Filtermat.**
10. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
11. Wash the filtermat once for 2 minutes with methanol.
12. Transfer the dried filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
13. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid.

Certificate of Analysis

RIPK1, active Sequence Information

<u>Protein</u>	Human RIPK1
<u>Tags</u>	C-terminal 6His
<u>Native sequence</u>	N2 of the recombinant protein is equivalent to N8 of human RIPK1
<u>Accession number</u>	GenBank NM_003804.3

Recombinant RIPK1 amino acid sequence:

```

1  MNVIKMKSSD  FLESAELDSG  GFGKVSLCFH  RTQGLMIMKT  VYKGPNCIEH  NEALLEEAKM
61  MNRLRHSRVV  KLLGVIIIEG  KYSLVMEYME  KGNLMHVLKA  EMSTPLSVKG  RIILEIIEGM
121  CYLHGKGVIIH  KDLKPENILV  DNDFHIKIAD  LGLASFKMWS  KLNNEEHNEL  REVDGTAKKN
181  GGTLYYMAPE  HLNDVNAKPT  EKSDVYSFAV  VLWAI FANKE  PYENAICEQQ  LIMCIKSGNR
241  PDVDDITEYC  PREIISLMKL  CWEANPEARP  TFPGIEEKFR  PFYLSQLEES  VEEDVKSLKK
301  EYSNENAVVK  RMQSLQGP GP  GHHHHHH

```

Recombinant RIPK1 nucleotide sequence:

```

1  atgaatgtca  ttaagatgaa  atccagtgc  ttctctggaga  gtgcagaact  ggacagcgga
61  ggcttcggga  aggtgtctct  gtgtttccac  agaaccagg  gactcatgat  catgaaaaca
121  gtgtacaagg  ggccaactg  cattgagcac  aacgaggccc  tcttggagga  ggcgaagatg
181  atgaacagac  tgagacacag  ccgggtggtg  aagctcctgg  gcgtcatcat  agaggaaggg
241  aagtactccc  tggatgatgga  gtacatggag  aagggaacc  tgatgcacgt  gctgaaagcc
301  gagatgagta  ctccgctttc  tgtaaaagga  aggataattt  tggaaatcat  tgaaggaatg
361  tgctacttac  atggaaaagg  cgtgatacac  aaggacctga  agcctgaaaa  tatecttggt
421  gataatgact  tccacattaa  gatcgagcac  ctccgcttg  cctcctttta  gatgtggagc
481  aaactgaata  atgaagagca  caatgagctg  agggaagtgg  acggcaccgc  taagaagaat
541  ggcgccaccc  tctactacat  ggcgcccgag  cacctgaatg  acgtcaacgc  aaagcccaca
601  gagaagtcgg  atgtgtacag  ctttgctgta  gtactctggg  cgatatttgc  aaataaggag
661  ccatatgaaa  atgctatctg  tgagcagcag  ttgataatgt  gcataaaatc  tgggaacagg
721  ccagatgtgg  atgacatcac  tgagtactgc  ccaagagaaa  ttatcagtct  catgaagctc
781  tgctgggaag  cgaatccgga  agctcggccg  acatttcctg  gcattgaaga  aaaatttagg
841  cttttttatt  taagtcaatt  agaagaaagt  gtagaagagg  acgtgaagag  tttaaagaaa
901  gagtattcaa  acgaaaatgc  agttgtgaag  agaatgcagt  ctcttcaagg  cccgggcccct
961  ggccatcacc  atcaccatca  ctaa

```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.